A new study has identified a potential safety concern associated with widely prescribed GLP-1 medications, finding that some patients taking the drugs may face an increased risk of dizziness, fainting and other complications related to low blood pressure.

The findings, which were presented over the weekend at ENDO 2026, the Endocrine Society's annual meeting, were based on an analysis of health records from more than 42,000 adults who were already taking at least two types of blood pressure medications when they began treatment with GLP-1 drugs such as semaglutide, tirzepatide or liraglutide.

What they're saying: Dr. Micah Eimer, a clinical assistant professor at Northwestern Medicine and senior author of the study, said the research was inspired by a pattern he noticed among patients taking GLP-1 medications.